942 resultados para Bainbridge, Edward Thomas
Resumo:
Bibliography : p. 178-179.
Resumo:
Mode of access: Internet.
Resumo:
Vol. 7 edited by James Craigie Robertson ... and J. Brigstocke Sheppard.
Resumo:
Includes index.
Resumo:
With reproductions of original title-pages.
Resumo:
Mode of access: Internet.
Resumo:
Mode of access: Internet.
Resumo:
Vols. I-III edited by C. E. Doble; vols. IV-V, by D. W. Rannie; vols. VI-VIII edited under the superintendence of the committee of the Oxford Historical Society; vols. IX-XI edited by H. E. Salter.
Resumo:
Bibliography: p. [627]-655.
Resumo:
The life of the author, essay on his works, and criticism on his history are translated from the French of Jean Baptiste de La Curne de Sainte-Palaye.
Resumo:
In 3 parts: the 1st an abridgment of Geoffrey of Monmouth's "Historia Britonum": the 2d, a history of the Anglo-Saxon and Norman kings to the death of Henry III; the 3d, a history of the reign of Edward I. The language is a specimen of the French of Yorkshire. cf. Introd.
Resumo:
Mode of access: Internet.
Resumo:
Sammelrezension von: 1. Edward W. Taylor / Patricia Cranton, and Associates (Hrsg.): The Handbook of Transformative Learning, Theory, Research, and Practice, San Francisco, CA: Jossey-Bass 2012 (598 S.; ISBN 978-1-111-21891-4) 2. Jack Mezirow / Edward W. Taylor, and Associates (Hrsg.): Transformative Learning in Practice, Insights from Community, Workplace, and Higher Education, San Francisco, CA: Jossey-Bass 2009 (303 S.; ISBN 978-0-470-25790-6)
Resumo:
Heparan sulfate mimetics, which we have called the PG500 series, have been developed to target the inhibition of both angiogenesis and heparanase activity. This series extends the technology underpinning PI-88, a mixture of highly sulfated oligosaccharides which reached Phase III clinical development for hepatocellular carcinoma. Advances in the chemistry of the PG500 series provide numerous advantages over PI-88. These new compounds are fully sulfated, single entity oligosaccharides attached to a lipophilic moiety, which have been optimized for drug development. The rational design of these compounds has led to vast improvements in potency compared to PI-88, based on in vitro angiogenesis assays and in vivo tumor models. Based on these and other data, PG545 has been selected as the lead clinical candidate for oncology and is currently undergoing formal preclinical development as a novel treatment for advanced cancer.